Drug intelligence / Profile preview

MP-204

Development stage: Unknown
Lead developer: Gensenta
Modality: Small Molecules
Administration: Topical

Overview

MP-204 is an investigational topical small molecule antiviral developed by Mustafa Nevzat İlaç Sanayii for the treatment of viral skin infections, particularly anogenital warts associated with Human Papillomavirus (HPV). Characterized by the developer as a 'best-in-class' therapy, the compound has completed Phase II clinical trials. While the specific molecular target or mechanism of action has not been publicly disclosed, it is designed for localized application to treat HPV-induced lesions.

Beyond the preview

Go deeper on MP-204.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MP-204.

Explore the full profile